Abridge AI Pilot Test

January 17, 2025 updated by: University of Colorado, Denver
We are piloting a new technology (Abridge) that uses artificial intelligence to listen to clinician-patient office visits and then document the interaction in the electronic health record.

Study Overview

Status

Active, not recruiting

Detailed Description

This study will evaluate pilot implementation of the Abridge Artificial Intelligence (AI) Platform (Abridge) in UCHealth clinics. Abridge licenses will be deployed to 116 physician and advanced practice clinicians to accomplish the following goals:

  1. Determine if Abridge meaningfully impacts clinician documentation time and burnout or stress
  2. Determine whether to scale Abridge beyond the pilot

We will evaluate clinician experiences using Abridge, particularly with regard to documentation time and clinician burnout or stress. Study findings will explore value added in integrating Abridge into clinician practice, and guide decision-making for entering into a commercial agreement with Abridge. This pilot will also inform best practices for scaling Abridge to a broader user base across UCHealth outpatient practices.

Study Type

Interventional

Enrollment (Estimated)

232

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Aurora, Colorado, United States, 80045
        • UCHealth

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

-clinician (physician, advance practice professional, or licensed mental health professional) employed by UCHealth

  • See clinic patients at least three half-day sessions per week. (Half-day sessions seeing or supervising patients with residents and fellows will NOT count toward the weekly total. Half-day sessions seeing patients with a medical student CAN count toward the weekly total, however, Abridge can only capture conversations where you are physically present with patients.)
  • Own an iOS smartphone and be willing to download and use the Epic Haiku smartphone app during clinic visits

Exclusion Criteria:

  • Trainees including residents and fellows
  • PT/OT, ED, maternal/fetal, pediatric, dental, eye specialties

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Assigned Abridge license
Providers assigned a license
Ambient AI for clinician documentation
Other Names:
  • Abridge
No Intervention: Control
Providers not assigned a license or waitlisted

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Burnout - High emotional exhaustion
Time Frame: Baseline, 2, 4 and 8 months
Validated measure collected by survey. Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC3475833/
Baseline, 2, 4 and 8 months
Burnout - High depersonalization
Time Frame: Baseline, 2, 4 and 8 months
Validated measure collected by survey. Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC3475833/
Baseline, 2, 4 and 8 months
Burnout - emotional exhaustion and depersonalization
Time Frame: Baseline, 2, 4 and 8 months
Validated measure collected by survey. Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC3475833/
Baseline, 2, 4 and 8 months
Time in notes per appointment
Time Frame: Baseline, 2, 4 and 8 months
Collected via EHR signal data
Baseline, 2, 4 and 8 months
Adoption
Time Frame: 2, 4 and 8 months
Percent of eligible visits in which intervention is used. Collected via EHR data
2, 4 and 8 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reach
Time Frame: 2, 4 and 8 months
Proportion and representativeness of eligible patients and visits intervention was used for
2, 4 and 8 months
Clinician experience
Time Frame: Baseline, 2, 4 and 8 months
Likelihood to recommend via validated NPS, qualitative drivers of experience, likelihood to change jobs, Weiners feasiblity/implementability/acceptability, system usability scale
Baseline, 2, 4 and 8 months
Time documenting
Time Frame: Baseline, 2, 4 and 8 months
Time spent documenting beyond appointment, average time in the EHR, time of last log out of the day, pajama time documenting
Baseline, 2, 4 and 8 months
Operational efficiency
Time Frame: Baseline, 2, 4 and 8 months
Same day note closure, average note star rating, average note turn around time
Baseline, 2, 4 and 8 months
Adoption
Time Frame: 2, 4 and 8 months
Abandonment rate and representativeness
2, 4 and 8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 13, 2025

Primary Completion (Estimated)

July 13, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

January 10, 2025

First Submitted That Met QC Criteria

January 10, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 17, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 24-1623

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Unsure if the third party owner of Abridge will allow sharing

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Clinician Experience

Clinical Trials on Ambient AI for clinician documentation

Subscribe